{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:45:07Z","timestamp":1794051907998,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oral nucleoside (acid) analogues (NAs) are recommended for patients with acute-on-chronic liver failure (ACLF) associated with hepatitis B virus (HBV-ACLF). The efficacy and safety of tenofovir (TDF) and entecavir (ETV) in these patients remain unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A comprehensive literature search in PubMed, Web of Science, The Cochrane Library, and Embase database was conducted to select studies published before December 2022 on TDF or ETV for HBV-ACLF. The primary outcomes were survival rates at 4, 12, and 48\u2009weeks. Secondary outcomes were virologic and biochemical responses, serum antigen conversion, liver function score, and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four prospective and one retrospective cohort studies were selected. The overall analysis showed comparable survival rates at 4, 12, and 48\u2009weeks for all patients receiving TDF or ETV (4-week: RR\u2009=\u20091.17, 95% CI: 0.90\u20131.51, <jats:italic>p<\/jats:italic>\u2009=\u20090.24; 12-week: RR\u2009=\u20091.00, 95% CI: 0.88\u20131.13, <jats:italic>p<\/jats:italic>\u2009=\u20090.94; 48-week: RR\u2009=\u20090.96, 95% CI: 0.58\u20131.57, <jats:italic>p<\/jats:italic>\u2009=\u20090.86). Child-Turcotte-Pugh (CTP) score and model for end-stage liver disease (MELD) score at 12\u2009weeks were comparable in both groups but lower than baseline (CTP: SMD\u2009=\u2009-0.75, 95% CI:-2.81\u20131.30, <jats:italic>p<\/jats:italic>\u2009=\u20090.47; MELD: SMD\u2009=\u2009-1.10, 95% CI:-2.29\u20130.08, <jats:italic>p<\/jats:italic>\u2009=\u20090.07). At 48\u2009weeks, estimated glomerular filtration rate (eGFR) levels were found to decrease to different degrees from baseline in both the TDF and ETV groups, and the decrease was greater in the TDF group than in the ETV group. No significant differences were found in biochemical, virologic response, and serum antigen conversion between the two groups during the observation period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>TDF treatment of HBV-ACLF is similar to ETV in improving survival, liver function, and virologic response but the effects on renal function in two groups in the long term remain unclear. More and larger long-term clinical trials are required to confirm these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-03024-7","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T08:01:32Z","timestamp":1699862492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Neng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sike","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"3024_CR1","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1136\/gutjnl-2017-314641","volume":"67","author":"T Wu","year":"2018","unstructured":"Wu T, Li J, Shao L, Xin J, Jiang L, Zhou Q, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67:2181\u201391.","journal-title":"Gut."},{"key":"3024_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-322161","volume":"71","author":"G Mezzano","year":"2022","unstructured":"Mezzano G, Juanola A, Cardenas A, Mezey E, Hamilton JP, Pose E, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut. 2022;71:148\u201355.","journal-title":"Gut."},{"key":"3024_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-0036-1583202","volume":"36","author":"V Arroyo","year":"2016","unstructured":"Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis, and clinical characteristics. Semin Liver Dis. 2016;36:109\u201316.","journal-title":"Semin Liver Dis."},{"key":"3024_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-0038-1657751","volume":"38","author":"L Yang","year":"2018","unstructured":"Yang L, Wu T, Li J, Li J. Bacterial infections in acute-on-chronic liver failure. Semin Liver Dis. 2018;38:121\u201333.","journal-title":"Semin Liver Dis."},{"key":"3024_CR5","doi-asserted-by":"publisher","first-page":"752875","DOI":"10.3389\/fmed.2021.752875","volume":"8","author":"A Khanam","year":"2021","unstructured":"Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med (Lausanne). 2021;8:752875.","journal-title":"Front Med (Lausanne)."},{"key":"3024_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/17474124.2018.1426459","volume":"12","author":"R-H Zhao","year":"2018","unstructured":"Zhao R-H, Shi Y, Zhao H, Wu W, Sheng J-F. Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert Rev Gastroenterol Hepatol. 2018;12:341\u201350.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"3024_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s12072-010-9204-4","volume":"4","author":"X Zhang","year":"2010","unstructured":"Zhang X, Ke W, Xie J, Zhao Z, Xie D, Gao Z. Comparison of effects of hepatitis E or a viral superinfection in patients with chronic hepatitis B. Hepatol Int. 2010;4:615\u201320.","journal-title":"Hepatol Int."},{"key":"3024_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jceh.2013.08.013","volume":"3","author":"A Kumar","year":"2013","unstructured":"Kumar A, Saraswat VA. Hepatitis E and acute-on-chronic liver failure. J Clin Exp Hepatol. 2013;3:225\u201330.","journal-title":"J Clin Exp Hepatol."},{"key":"3024_CR9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","volume":"137","author":"F Zoulim","year":"2009","unstructured":"Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608.e1-2.","journal-title":"Gastroenterology."},{"key":"3024_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology."},{"key":"3024_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u201383.","journal-title":"Hepatology."},{"issue":"67","key":"3024_CR12","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u201398.","journal-title":"J Hepatol."},{"key":"3024_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/infdis\/jiu471","volume":"211","author":"US Gill","year":"2015","unstructured":"Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJW, Barr DA, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211:374\u201382.","journal-title":"J Infect Dis."},{"key":"3024_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/jac\/dku502","volume":"70","author":"P Maggi","year":"2015","unstructured":"Maggi P, Montinaro V, Leone A, Fasano M, Volpe A, Bellacosa C, et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. J Antimicrob Chemother. 2015;70:1150\u20134.","journal-title":"J Antimicrob Chemother."},{"key":"3024_CR15","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s10620-010-1257-7","volume":"55","author":"Y-L Cui","year":"2010","unstructured":"Cui Y-L, Yan F, Wang Y-B, Song X-Q, Liu L, Lei X-Z, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373\u201380.","journal-title":"Dig Dis Sci."},{"key":"3024_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336\u201341.","journal-title":"Int J Surg."},{"key":"3024_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:353\u201390.","journal-title":"Hepatol Int."},{"key":"3024_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol."},{"key":"3024_CR19","first-page":"5728359","volume":"2020","author":"K Zhang","year":"2020","unstructured":"Zhang K, Lin S, Wang M, Huang J, Zhu Y. The risk of acute kidney injury in hepatitis B virus-related acute on chronic liver failure with Tenofovir treatment. Biomed Res Int. 2020;2020:5728359.","journal-title":"Biomed Res Int."},{"key":"3024_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","volume":"21","author":"J Li","year":"2021","unstructured":"Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, et al. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infect Dis. 2021;21:567.","journal-title":"BMC Infect Dis."},{"key":"3024_CR21","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1097\/MCG.0000000000001038","volume":"53","author":"Y-M Wan","year":"2019","unstructured":"Wan Y-M, Li Y-H, Xu Z-Y, Wu H-M, Xu Y, Wu X-N, et al. Tenofovir versus Entecavir for the treatment of acute-on-chronic liver failure due to reactivation of chronic hepatitis B with genotypes B and C. J Clin Gastroenterol. 2019;53:e171\u20137.","journal-title":"J Clin Gastroenterol."},{"key":"3024_CR22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jvh.13468","volume":"28","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Xu W, Zhu X, Li X, Li J, Shu X, et al. The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: a prospective cohort study. J Viral Hepat. 2021;28:592\u2013600.","journal-title":"J Viral Hepat."},{"key":"3024_CR23","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.4103\/jfmpc.jfmpc_2299_20","volume":"10","author":"SMS Hossain","year":"2021","unstructured":"Hossain SMS, Mahtab MA, Das DC, Noor-E-Alam SM, Mamun AA, Khan MSI, et al. Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure. J Family Med Prim Care. 2021;10:2642\u20135.","journal-title":"J Family Med Prim Care."},{"issue":"1426\u201337","key":"3024_CR24","first-page":"1437.e1","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(1426\u201337):1437.e1-1437.e9.","journal-title":"Gastroenterology."},{"key":"3024_CR25","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.3748\/wjg.v20.i43.16037","volume":"20","author":"CA Philips","year":"2014","unstructured":"Philips CA, Sarin SK. Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation. World J Gastroenterol. 2014;20:16037\u201352.","journal-title":"World J Gastroenterol."},{"issue":"Suppl 1","key":"3024_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/liv.12398","volume":"34","author":"C P\u00e9rez-Cameo","year":"2014","unstructured":"P\u00e9rez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in HBV: when to stop NAs. Liver Int. 2014;34(Suppl 1):146\u201353.","journal-title":"Liver Int."},{"key":"3024_CR27","doi-asserted-by":"publisher","first-page":"e0224773","DOI":"10.1371\/journal.pone.0224773","volume":"14","author":"M Chen","year":"2019","unstructured":"Chen M, Wang H, Zheng Q, Zheng X, Fan J, Ding Y, et al. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: a systematic review and meta-analysis. PLoS One. 2019;14:e0224773.","journal-title":"PLoS One."},{"key":"3024_CR28","doi-asserted-by":"publisher","first-page":"e98865","DOI":"10.1371\/journal.pone.0098865","volume":"9","author":"W Ke","year":"2014","unstructured":"Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, et al. Comparison of efficacy and safety of Tenofovir and Entecavir in chronic hepatitis B virus infection: a systematic review and Meta-analysis. PLoS One. 2014;9:e98865.","journal-title":"PLoS One."},{"key":"3024_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/jvh.13400","volume":"28","author":"D Con","year":"2021","unstructured":"Con D, Goodwin T, Majeed A, Roberts S, Kemp W. Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: a network meta-analysis. J Viral Hepat. 2021;28:40\u201350.","journal-title":"J Viral Hepat."},{"key":"3024_CR30","first-page":"354908","volume":"2011","author":"B Fernandez-Fernandez","year":"2011","unstructured":"Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Ni\u00f1o MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.","journal-title":"AIDS Res Treat."},{"key":"3024_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/apt.14497","volume":"47","author":"GL-H Wong","year":"2018","unstructured":"Wong GL-H, Seto W-K, Wong VW-S, Yuen M-F, Chan HL-Y. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47:730\u20137.","journal-title":"Aliment Pharmacol Ther."},{"key":"3024_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/jvh.13222","volume":"27","author":"TS Lim","year":"2020","unstructured":"Lim TS, Lee JS, Kim BK, Lee HW, Jeon MY, Kim SU, et al. An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. J Viral Hepat. 2020;27:316\u201322.","journal-title":"J Viral Hepat."},{"key":"3024_CR33","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2147\/TCRM.S143286","volume":"13","author":"Y-M Yang","year":"2017","unstructured":"Yang Y-M, Choi EJ. Renal safety of tenofovir and\/or entecavir in patients with chronic HBV monoinfection. TCRM. 2017;13:1273\u201385.","journal-title":"TCRM."},{"key":"3024_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijid.2022.09.021","volume":"124","author":"X Yang","year":"2022","unstructured":"Yang X, Yan H, Zhang X, Qin X, Guo P. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis. Int J Infect Dis. 2022;124:133\u201342.","journal-title":"Int J Infect Dis."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03024-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T08:02:15Z","timestamp":1699862535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03024-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3024"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03024-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interest"}},{"value":"As a meta-analysis, our paper did not require any referral to our institutional clinical ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"388"}}